ArticleBioactive materials2025
Therapeutic silicate biomaterials for sarcopenia treatment by inhibiting inflammation and enhancing muscle regeneration through regulation of Sarcolipin/SIRT signaling pathway.
Article in Bioactive materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- An Emodin-Depot Microsphere-in-Hydrogel Reprograms the Immuno-myogenic Niche to Enable Volumetric Muscle Loss Repair Revealed by Single-Cell Profiling.Research (Washington, D.C.) · 2026Article
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Based on the observation of silicon content decrease in the muscles and serum with aging, this study proposes a silicate bioactive material based therapy for treating sarcopenia. Two therapeutic strategies were designed. One utilizes calcium silicate (CS) hydrogel for localized intramuscular treatment, and the other employs CS solution for systemic treatment through Intravenous injection. Both treatments restore silicon levels in the muscles and serum of aging mice, and show therapeutic effects on sarcopenia. Specifically, the CS hydrogel demonstrates more pronounced short-term efficacy in promoting local muscle regeneration, while the CS solution exhibits superior outcomes in modulating the overall condition of aging mice. The fundamental mechanism of the CS treatments on sarcopenia may involve the direct regulation of the SIRTs signaling pathway by silicate ions released from CS, as well as the indirect regulation of SIRTs pathway via the suppression of Sarcolipin (SLN) overexpression by silicate ions. Specifically, silicate ions directly upregulate SIRT1 expression in macrophages and on one side promote NF-kB deacetylation to inhibit M1 polarization, and on the other side facilitate STAT3 deacetylation to inhibit M2 polarization, ultimately reducing the expression of inflammatory factors (TNF-α, IL-6) and fibrotic factors (IL-10, TGF-β). Meanwhile, silicate ions directly upregulate SIRT3 in myoblasts, leading to the promotion of STAT3 dephosphorylation, inhibits mitochondrial reactive oxygen species (ROS) secretion, and enhances the expression of MyoD, MyoG, and Myosin, and accelerates myogenic differentiation. This bioactive CS based therapy provides a new approach for combating sarcopenia.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.